Today: 29 April 2026
Browse Category

NASDAQ:ITCI 27 June 2025

Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

Top Biotechnology and Health Tech Trends in 2025: Mid-Year Update and Forecast (Updated: June 27th, 2025)

The FDA approved Abeona’s Zevaskyn, the first cell-based gene therapy for RDEB, in April 2025, with launch set for Q3 at $3.1 million. Vertex’s CRISPR therapy Casgevy generated $2 million in Q3 2024. Novo Holdings acquired Catalent for $16.5 billion in January 2025 to secure GLP-1 drug manufacturing. Johnson & Johnson bought Intra-Cellular Therapies for $14.6 billion, expanding its neuroscience portfolio.

Stock Market Today

  • Diversified Royalty (TSE:DIV) Stock Price Surpasses 50-Day Moving Average Amid Upgraded Analyst Ratings
    April 29, 2026, 4:59 AM EDT. Diversified Royalty Corp's stock (TSE:DIV) climbed above its 50-day moving average of C$4.18, reaching C$4.23 in Tuesday's trading. The company, a multi-royalty firm focused on acquiring royalties from North American franchisors, holds a market cap of C$716.53 million and a price-to-earnings ratio near 20. Analysts, including Desjardins, recently raised the target price from C$4.00 to C$4.50 with a "buy" rating. The stock shows a 6.8% dividend yield, with monthly payments starting April 30. Diversified Royalty's quarterly EPS hit C$0.06, backed by strong returns and net margins. Investors note the company's 126.79% payout ratio and expect EPS of 0.2 for the year, signaling ongoing financial stability.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 29.04.2026

29 April 2026
LIVEMarkets rolling coverageStarted: April 29, 2026, 12:00 AM EDTUpdated: April 29, 2026, 5:06 AM EDT Diversified Royalty (TSE:DIV) Stock Price Surpasses 50-Day Moving Average Amid Upgraded Analyst Ratings April 29, 2026, 4:59 AM EDT. Diversified Royalty Corp's stock (TSE:DIV) climbed above its 50-day moving average of C$4.18, reaching C$4.23 in Tuesday's trading. The company, a multi-royalty firm focused on acquiring royalties from North American franchisors, holds a market cap of C$716.53 million and a price-to-earnings ratio near 20. Analysts, including Desjardins, recently raised the target price from C$4.00 to C$4.50 with a "buy" rating. The stock shows a 6.8% dividend
AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

29 April 2026
AST SpaceMobile will hold its first-quarter update call on May 11 after winning FCC approval to deploy a 248-satellite constellation for direct-to-device service. Shares fell 6.8% Tuesday, following the loss of its BlueBird 7 satellite in a failed launch. The company expects insurance to cover the loss and is targeting 45 satellites in orbit by end-2026. Investors are watching launch progress and commercial service timing.
Go toTop